Recent findings suggest that leukaemia inhibitory factor receptor sensitises hepatocellular carcinoma to Sorafenib treatment through regulating the expression of iron‐sequestering cytokine lipocalin 2 (LCN2).52 The gene discussed is LCN2; the disease is hepatocellular carcinoma.